Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections.
One of the major causes of morbidity and mortality in man and economically important animals is bacterial infections of the gastrointestinal (GI) tract. The emergence of difficult-to-treat infections, primarily caused by antibiotic resistant bacteria, demands for alternatives to antibiotic therapy. Currently, one of the emerging therapeutic alternatives is the use of lytic bacteriophages. In an effort to exploit the target specificity and therapeutic potential of bacteriophages, we examined the utility of bacteriophage tailspike proteins (Tsps). Among the best-characterized Tsps is that from the Podoviridae P22 bacteriophage, which recognizes the lipopolysaccharides of Salmonella enterica serovar Typhimurium. In this study, we utilized a truncated, functionally equivalent version of the P22 tailspike protein, P22sTsp, as a prototype to demonstrate the therapeutic potential of Tsps in the GI tract of chickens. Bacterial agglutination assays showed that P22sTsp was capable of agglutinating S. Typhimurium at levels similar to antibodies and incubating the Tsp with chicken GI fluids showed no proteolytic activity against the Tsp. Testing P22sTsp against the three major GI proteases showed that P22sTsp was resistant to trypsin and partially to chymotrypsin, but sensitive to pepsin. However, in formulated form for oral administration, P22sTsp was resistant to all three proteases. When administered orally to chickens, P22sTsp significantly reduced Salmonella colonization in the gut and its further penetration into internal organs. In in vitro assays, P22sTsp effectively retarded Salmonella motility, a factor implicated in bacterial colonization and invasion, suggesting that the in vivo decolonization ability of P22sTsp may, at least in part, be due to its ability to interfere with motility… Our findings show promise in terms of opening novel Tsp-based oral therapeutic approaches against bacterial infections in production animals and potentially in humans.
Institute for Biological Sciences, National Research Council of Canada, Ottawa, Canada.
Shakeeba
S
Waseh
Pejman
P
Hanifi-Moghaddam
Russell
R
Coleman
Michael
M
Masotti
Shannon
S
Ryan
Mary
M
Foss
Roger
R
MacKenzie
Matthew
M
Henry
Christine M
CM
Szymanski
Jamshid
J
Tanha
D000284:Administration, Oral; D000371:Agglutination / Q000276:immunology; D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects; D017100:Bacteriophage P22 / Q000378:metabolism*; D002432:Cecum / Q000187:drug effects / Q000382:microbiology; D002645:Chickens; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000382:microbiology; D006026:Glycoside Hydrolases; D008099:Liver / Q000187:drug effects / Q000382:microbiology; D010447:Peptide Hydrolases / Q000378:metabolism; D012481:Salmonella Infections, Animal / Q000188:drug therapy* / Q000382:microbiology; D012486:Salmonella typhimurium / Q000254:growth & development* / Q000276:immunology / Q000821:virology; D013154:Spleen / Q000187:drug effects / Q000382:microbiology; D017376:Viral Tail Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000378:metabolism
D017376:Viral Tail Proteins; D006026:Glycoside Hydrolases; C083268:tailspike protein, bacteriophage; D010447:Peptide Hydrolases